ALLMedicine™ Lung Cancer Immunotherapy Center

Dec 10th, 2020 - Anti-PD-(L)1 therapy represents a turning point in lung cancer immunotherapy, moving from previously ineffective enhancer strategies to immune checkpoints as standard first- and second-line therapies. This unprecedented success highlights the impo...

Nov 14th, 2020 - It has been reported that a group of patients with advanced non-small cell lung cancer showed circulating T cells with a senescent phenotype, and an abundance of such cells is associated with worse clinical response to immune checkpoint inhibitors...

Nov 20th, 2019 - Despite substantial progress in lung cancer immunotherapy, the overall response rate in patients with KRAS-mutant lung adenocarcinoma (LUAD) remains low. Combining standard immunotherapy with adjuvant approaches that enhance adaptive immune respon...

Jul 29th, 2019 - The autoimmune adverse effects of lung cancer immunotherapy are not fully understood at the population level. Using observational data from commercial health insurance claims, we compared autoimmune diseases risk of immune checkpoint inhibitors (i...

May 20th, 2019 - We previously showed that therapy with anti-checkpoints T-lymphocyte-associated protein 4 (anti-CTLA-4) or antiprogrammed cell death protein 1 (anti-PD-1) agents was more effective for men as compared with women. However, because the sex-dimorphis...

Dec 16th, 2018 - Since the 2015 WHO classification was introduced into clinical practice, the importance of immunohistochemistry (IHC) has figured prominently in lung cancer diagnosis. In addition to distinction of small versus non-small cell carcinoma (NSCC), pat.

Mar 19th, 2018 - In response to advances in the field, the College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association forMolecular Pathology (AMP) recently updated their recommendations for molec.

Sep 30th, 2017 - The IASLC Atlas of PD-L1 Immunohistochemistry Testing in Lung Cancer is a new resource for understanding programmed cell death ligand-1 (PD-L1) immunohistochemistry (IHC) assays.

Sep 30th, 2017 - The IASLC Atlas of EGFR Testing in Lung Cancer provides health care professionals with information on EGFR testing processes and facilitates clinicians’ understanding of how to interpret the results.

Dec 10th, 2020 - Anti-PD-(L)1 therapy represents a turning point in lung cancer immunotherapy, moving from previously ineffective enhancer strategies to immune checkpoints as standard first- and second-line therapies. This unprecedented success highlights the impo...

Nov 14th, 2020 - It has been reported that a group of patients with advanced non-small cell lung cancer showed circulating T cells with a senescent phenotype, and an abundance of such cells is associated with worse clinical response to immune checkpoint inhibitors...

Jan 22nd, 2020 - We've just come to the end of a remarkable decade of progress that has transformed how we treat—and, indeed, even how we view—lung cancer. Rewind 10 years: As we entered 2010, median survival for patients with metastatic non-small cell lung cancer...

Nov 20th, 2019 - Despite substantial progress in lung cancer immunotherapy, the overall response rate in patients with KRAS-mutant lung adenocarcinoma (LUAD) remains low. Combining standard immunotherapy with adjuvant approaches that enhance adaptive immune respon...

Sep 19th, 2019

Jan 22nd, 2020 - We've just come to the end of a remarkable decade of progress that has transformed how we treat—and, indeed, even how we view—lung cancer. Rewind 10 years: As we entered 2010, median survival for patients with metastatic non-small cell lung cancer...

Sep 19th, 2019

Sep 19th, 2019 - An electronic “nose” that detects chemicals in the breath of lung cancer patients may help distinguish between those who will and will not respond to immunotherapy, a new study suggests. In the small study, the eNose was better at identifying the ...

Sep 19th, 2019

Nov 22nd, 2018 - In two separate announcements this week, the National Institute for Health and Care Excellence (NICE) recommended pembrolizumab (Keytruda, Merck Sharpe & Dohme) as a treatment option for certain types of lung cancer, as well as for some patients w...